Chi-Med’s surufatinib bags US fast track designations
The drug has a unique dual mechanism of action that could help fulfil an unmet medical need
Read More
Tag: NET
NICE backs Afinitor, Sutent for neuroendocrine tumours
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
